-
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non–Hodgkin Lymphoma
A recent first-in-human phase I study shows the safety and preliminary efficacy of nemtabrutinib in…